Cargando…
Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review
BACKGROUND: The purpose of this study was to carry an extended literature review to compare antimuscarnics with beta adrenergic agonists (mirabegron) in treatment of overactive bladder. MATERIALS AND METHODS: A literature review was carried out, using key words in different databases including MEDLI...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451319/ https://www.ncbi.nlm.nih.gov/pubmed/34552455 http://dx.doi.org/10.1097/CU9.0000000000000037 |
_version_ | 1784569817530892288 |
---|---|
author | Wani, Mudassir M. Sheikh, Mohammad I. Bhat, Tahir Bhat, Zubair Bhat, Arshad |
author_facet | Wani, Mudassir M. Sheikh, Mohammad I. Bhat, Tahir Bhat, Zubair Bhat, Arshad |
author_sort | Wani, Mudassir M. |
collection | PubMed |
description | BACKGROUND: The purpose of this study was to carry an extended literature review to compare antimuscarnics with beta adrenergic agonists (mirabegron) in treatment of overactive bladder. MATERIALS AND METHODS: A literature review was carried out, using key words in different databases including MEDLINE, PUBMED, and EMBASE. All relevant published articles during last 5 years with full texts available were included in this review for critical analysis and evaluation. In total, there were 20 studies including 7 systemic reviews, 6 retrospective cohort, 3 prospective cohort, 2 randomized controlled trials, and 2 cross sectional studies. RESULTS: After critical evaluation the results were considered under parameters of efficacy, adverse effects, adherence and persistence, tolerability, cost-effectiveness. In 9 studies efficacy was evaluated, 5 studies dealt with adverse effects, same number evaluated adherence and persistence. Cost effectiveness was compared in 3 and same number of studies also compared tolerability. CONCLUSIONS: To conclude, we found mirabegron is as efficacious as any other antimuscarnics, has better tolerability (including elderly), has better adverse effect profile, is cost effective, has better persistence and adherence rates at 12 months. |
format | Online Article Text |
id | pubmed-8451319 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-84513192021-09-21 Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review Wani, Mudassir M. Sheikh, Mohammad I. Bhat, Tahir Bhat, Zubair Bhat, Arshad Curr Urol Review BACKGROUND: The purpose of this study was to carry an extended literature review to compare antimuscarnics with beta adrenergic agonists (mirabegron) in treatment of overactive bladder. MATERIALS AND METHODS: A literature review was carried out, using key words in different databases including MEDLINE, PUBMED, and EMBASE. All relevant published articles during last 5 years with full texts available were included in this review for critical analysis and evaluation. In total, there were 20 studies including 7 systemic reviews, 6 retrospective cohort, 3 prospective cohort, 2 randomized controlled trials, and 2 cross sectional studies. RESULTS: After critical evaluation the results were considered under parameters of efficacy, adverse effects, adherence and persistence, tolerability, cost-effectiveness. In 9 studies efficacy was evaluated, 5 studies dealt with adverse effects, same number evaluated adherence and persistence. Cost effectiveness was compared in 3 and same number of studies also compared tolerability. CONCLUSIONS: To conclude, we found mirabegron is as efficacious as any other antimuscarnics, has better tolerability (including elderly), has better adverse effect profile, is cost effective, has better persistence and adherence rates at 12 months. Lippincott Williams & Wilkins 2021-09 2021-08-17 /pmc/articles/PMC8451319/ /pubmed/34552455 http://dx.doi.org/10.1097/CU9.0000000000000037 Text en Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. http://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) |
spellingShingle | Review Wani, Mudassir M. Sheikh, Mohammad I. Bhat, Tahir Bhat, Zubair Bhat, Arshad Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review |
title | Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review |
title_full | Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review |
title_fullStr | Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review |
title_full_unstemmed | Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review |
title_short | Comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: A literary review |
title_sort | comparison of antimuscarinic drugs to beta adrenergic agonists in overactive bladder: a literary review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8451319/ https://www.ncbi.nlm.nih.gov/pubmed/34552455 http://dx.doi.org/10.1097/CU9.0000000000000037 |
work_keys_str_mv | AT wanimudassirm comparisonofantimuscarinicdrugstobetaadrenergicagonistsinoveractivebladderaliteraryreview AT sheikhmohammadi comparisonofantimuscarinicdrugstobetaadrenergicagonistsinoveractivebladderaliteraryreview AT bhattahir comparisonofantimuscarinicdrugstobetaadrenergicagonistsinoveractivebladderaliteraryreview AT bhatzubair comparisonofantimuscarinicdrugstobetaadrenergicagonistsinoveractivebladderaliteraryreview AT bhatarshad comparisonofantimuscarinicdrugstobetaadrenergicagonistsinoveractivebladderaliteraryreview |